Lei Pang

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

First-line Pembrolizumab, Urology, Metastatic Urothelial Cancer +7

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Drew J. Winston, Kathleen M. Mullane, Oliver A. Cornely et al. · The Lancet · 2018 · 93 citations

Vaccination, Transplantation, Marrow Transplantation +8

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults

Myron J. Levin, Kenneth E. Schmader, Lei Pang et al. · The Journal of Infectious Diseases · 2015 · 71 citations · Full text

Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

Peter H. O’Donnell, Petros Grivas, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2017 · 63 citations

First-line Pembrolizumab, Cisplatin-ineligible Advanced Uc, Oncology +17

Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

Arjun Vasant Balar, Joaquim Bellmunt, Peter H. O’Donnell et al. · Annals of Oncology · 2016 · 61 citations

Metastatic Urothelial Cancer, Urology, Genitourinary Cancer +7